Medical Cannabis Market - Size, Share, Trends, and Forecast to 2027

The Global Medical Cannabis Market, by Point of Sale (Dispensaries, Online Pharmacy, Hospital Pharmacy), by Active Ingredient (Tetrahydrocannabinol (THC) and Cannabidiol (CBD)) and by Therapeutic Application (Pain, Arthritis, Neurological Disease (Epilepsy, Multiple Sclerosis and Other Neurological Applications), and Other Applications) was valued at US$ 3,520.7 million in 2017 and is projected to exhibit a CAGR of 24.4% over the forecast period (2017 - 2025), as highlighted in a new report published by Coherent Market Insights.

The legalization of medicinal cannabis would result in more research, offering a valuable medical option for the treatment of various symptoms, such as chemotherapy induced side effects, epilepsy, and chronic pain, which in turn is expected to support growth of medical cannabis market in the near future. In February 2016, the Australian government amended the Narcotics Drugs Act 1967 to allow cultivation of cannabis for medicinal or scientific purposes under a national licensing scheme, which is expected to favor the growth of the medical cannabis market in the region. Furthermore, the Australian government on January 2018, announced that it would allow medicinal cannabis exports, which is expected to provide growth opportunities for domestic manufacturers.

Browse 32 Market Data Tables and 31 Figures spread through 191 Pages and in-depth TOC on ""Medical Cannabis Market, by Point of Sale (Dispensaries, Online Pharmacy, Hospital Pharmacy), by Active Ingredient (Tetrahydrocannabinol (THC) and Cannabidiol (CBD)) and by Therapeutic Application (Pain, Arthritis, Neurological Disease (Epilepsy, Multiple Sclerosis and Other Neurological Applications), Other Applications) - Global Forecast to 2025""

To know the latest trends and insights related to medical cannabis market, click the link below:

https://www.coherentmarketinsights.com/market-insight/medicinal-cannabis-market-40

Increasing clinical trials and approvals of the medicinal cannabis products are expected to fuel growth of the medical cannabis market over the forecast period. For instance, in July 2017, 18 states in the U.S. allowed the use of Cannabidiol (CBD) extract, majorly in oil form with minimal tetrahydrocannabinol (THC), which is used for the treatment of epilepsy or seizures in seriously ill children. Manufacturers are focused on developing drugs with medicinal cannabis in order to offer enhanced treatment for various diseases such as epilepsy and various types of cancers. For instance, GW Pharmaceuticals' Epidiolex (cannabidivarin) is in developmental process and is used in clinical trials for the treatment of resistant epilepsy, supported by NSW and Queensland government. Moreover, in 2016, the UK Government gave GW Pharmaceuticals a special permission to investigate medicines derived from cannabis, which are used in treatment of a range of symptoms. Advertising laws are very stringent in majority of the economies, where cannabis are legalized for medical or recreational use. As most economies prohibit open advertising that exposes minors and other vulnerable members of society to the availability of marijuana.

Furthermore, due to the federal classification of marijuana as a Class I drug, mainstream media channels are hesitant about accepting advertising for cannabis-related products and services. Due to such restrictions, medicinal cannabis manufacturers use three options to market marijuana related products: direct mail, email, and SMS messaging. Among these, SMS messaging is the most effective way of marketing, as it reaches to consumers more quickly than direct mail and has a broader reach than email. Furthermore, SMS messaging service is used for offering discount coupons and latest promotion of the products. In December 2017, 17 of Canada's licensed cannabis producers (LPs), representing around 90% of the current legal medical cannabis market in the economy, along with the Canadian Medicinal Cannabis Council developed guidelines to facilitate responsible branding and promotion of cannabis in Canada.

However, highly addictive nature of cannabis where users can become dependent on it experiencing withdrawal symptoms for a time, when they stop using it can hamper growth of the market.

Key Takeaways of the Medical Cannabis Market:

The global medical cannabis market is expected to exhibit a CAGR of 24.4% over the forecast period (2017-2025). This is attributed to increasing prevalence of chronic disease and increasing approvals of the medicinal cannabis in the various economies.
Among Active Ingredient types, Cannabidiol segment is expected to account for the largest share in the global medical cannabis market over the forecast period. This is attributed to increasing use of Cannabidiol in oil form. For instance, in U.S., July 2017, 18 states allows the use of CBD extract, usually in oil form, with minimal tetrahydrocannabinol (THC), majorly for the treatment of epilepsy or seizures in seriously ill children.
Increasing adaptation of the mobile application, e-commerce and digital media is expected to drive growth of the online cannabis pharmacy market. Furthermore, cannabis-related online content, directories and online marketing is spreading the awareness regarding medicinal benefits of the cannabis products, which in turn is driving growth of the market.
Among therapeutic application, pain segment accounted for the largest market share, owing to increasing incidence of chronic pain, which causes a significant economic and social burden. According to the World Health Organization (WHO) data released in 2015, around 20% of the worldwide population, annually suffers from some form of chronic pain, which includes fibromyalgia, back pain, neck pain, chronic fatigue syndrome, temporomandibular joint disorders, sciatica, headaches, and itchiness.
Some of the major players operating in the global medical cannabis market include BOL Pharma, Tilray, Medreleaf Corporation, Aurora Cannabis, Inc., Canopy Growth Corporation, Insys Therapeutics, Inc., Aphria, Inc., MGC Pharmaceuticals Limited, GW Pharmaceuticals, plc, and Medical Marijuana Inc.